Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system

J Radiat Res. 2022 Jul 19;63(4):620-635. doi: 10.1093/jrr/rrac030.

Abstract

The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measurement methods, and to determine tolerance level for each QA measurement for a commercially available accelerator-based BNCT system. In order to establish a system of dosimetric QA suitable for BNCT, the following steps were taken. First, standard measurement points based on tissue-administered doses in BNCT for brain tumors were defined, and clinical tolerances of dosimetric QA measurements were derived from the contribution to total tissue relative biological effectiveness factor-weighted dose for each dose component. Next, a QA program was proposed based on TG-142 and TG-198, and confirmed that it could be assessed whether constancy of each dose component was assured within the limits of tolerances or not by measurements of the proposed QA program. Finally, the validity of the BNCT QA program as an evaluation system was confirmed in a demonstration experiment for long-term measurement over 1 year. These results offer an easy, reliable QA method that is clinically applicable with dosimetric validity for the mixed irradiation field of accelerator-based BNCT.

Keywords: accelerator-based boron neutron capture therapy; dosimetric quality assurance.

MeSH terms

  • Boron Neutron Capture Therapy* / methods
  • Brain Neoplasms* / radiotherapy
  • Gamma Rays
  • Humans
  • Neutrons
  • Radiometry
  • Relative Biological Effectiveness